Patents by Inventor Steven Harper

Steven Harper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110224134
    Abstract: The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections.
    Type: Application
    Filed: May 20, 2011
    Publication date: September 15, 2011
    Applicants: Istituto Di Ricerche Di Biologia Molecolare P. Angeletti SPA, Merck Sharp & Dohme Corp.
    Inventors: Steven Harper, Vincenzo Summa, Nigel J. Liverton, John A. McCauley
  • Patent number: 7973040
    Abstract: The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections.
    Type: Grant
    Filed: July 17, 2009
    Date of Patent: July 5, 2011
    Assignees: Merck Sharp & Dohme Corp., Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA
    Inventors: Steven Harper, Vincenzo Summa, Nigel J. Liverton, John A. McCauley
  • Patent number: 7879815
    Abstract: The present invention provides nucleoside aryl phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside aryl phosphoramidates alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside aryl phosphoramidates of the present invention.
    Type: Grant
    Filed: February 12, 2007
    Date of Patent: February 1, 2011
    Assignees: Merck Sharp & Dohme Corp., Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Malcolm MacCoss, David B. Olsen, Monica Donghi, Cristina Gardelli, Steven Harper, Malte Meppen, Frank Narjes, Barbara Pacini
  • Publication number: 20110002884
    Abstract: A class of macrocyclic compounds of formula (I), wherein R1, R3, R4, Ra, Rb, A, B, Z, M, W and n are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection.
    Type: Application
    Filed: February 12, 2009
    Publication date: January 6, 2011
    Inventors: John A. McCauley, Nigel J. Liverton, Steven Harper, Charles J. McIntyre, Michael T. Rudd
  • Publication number: 20100305034
    Abstract: An isolated VEGF polypeptide having anti-angiogenic activity, said polypeptide including the amino acid sequence of SEQ.ID NO.1, or variants thereof.
    Type: Application
    Filed: April 27, 2010
    Publication date: December 2, 2010
    Applicant: UNIVERSITY OF BRISTOL
    Inventors: DAVID BATES, STEVEN HARPER
  • Patent number: 7820178
    Abstract: An isolated VEGF polypeptide having anti-angiogenic activity, said polypeptide including the amino acid sequence of SEQ. ID NO. 1, or variants thereof.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: October 26, 2010
    Assignee: University of Brisol
    Inventors: David Bates, Steven Harper
  • Publication number: 20100234316
    Abstract: The present invention provides nucleoside aryl phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside aryl phosphoramidates alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside aryl phosphoramidates of the present invention.
    Type: Application
    Filed: February 12, 2007
    Publication date: September 16, 2010
    Inventors: Malcolm MacCoss, David B. Olsen, Monica Donghi, Cristina Gardelli, Steven Harper, Malte Meppen, Frank Narjes, Barbara Pacini
  • Publication number: 20100183551
    Abstract: A class of macrocyclic compounds of formula (I), wherein R1, R3, R4, Ra, Rb, A, Z, Y, X, M, W, n and m are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes 5 for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection.
    Type: Application
    Filed: July 17, 2008
    Publication date: July 22, 2010
    Inventors: Steven Harper, Vincenzo Summa, Nigel J. Liverton, John A. McCauley, John W. Butcher, Marcello Di Filippo, Maria Emilia Di Francesco, Marco Ferrara, Joseph J. Romano, Michael T. Rudd
  • Publication number: 20100099695
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Application
    Filed: October 23, 2007
    Publication date: April 22, 2010
    Inventors: Nigel J. Liverton, Vincenzo Summa, Maria Emilia Di Francesco, Marco Ferrara, Kevin F. Gilbert, Steven Harper, John A. McCauley, Charles A. McIntyre, Alessia Petrocchi, Marco Pompei, Joseph J. Romano, Michael T. Rudd, John W. Butcher, M. Katharine Holloway
  • Publication number: 20100029666
    Abstract: The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections.
    Type: Application
    Filed: July 17, 2009
    Publication date: February 4, 2010
    Inventors: Steven Harper, Vincenzo Summa, Nigel J. Liverton, John A. McCauley
  • Publication number: 20090312241
    Abstract: The present invention relates to macrocyclic compounds of formula (I): wherein W, n, m, R1, R2, R3, R4, R5, Ra, M, Z and ring B are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.
    Type: Application
    Filed: June 21, 2007
    Publication date: December 17, 2009
    Applicant: Istituto di Ricerche di Biologia Molecolare P. Angeletti SPA
    Inventors: Benedetta Crescenzi, Monica Donghi, Marco Ferrara, Cristina Gardelli, Steven Harper, Uwe Koch, Michael Rowley, Vincenzo Summa
  • Publication number: 20090136449
    Abstract: The present invention relates to tetracyclic indole derivatives of formula (I); wherein Ar, D1, D2, D3, D4, W, X, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.
    Type: Application
    Filed: November 9, 2006
    Publication date: May 28, 2009
    Inventors: Marcello Di Filippo, Steven Harper, Frank Narjes, Barbara Pacini, Alessia Petrocchi, Michael Rowley, Ian Stansfield
  • Patent number: 7459452
    Abstract: 4,5-Dihydroxypyrimidine-6-carboxamides of formula: are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein R1, R2, R3 and R4 are defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: September 7, 2006
    Date of Patent: December 2, 2008
    Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Maria E. Di Francesco, Cristina Gardelli, Steven Harper, Victor G. Matassa, Ester Murgalia, Emanuela Nizi, Paola Pace, Barbara Pacini, Alessia Petrocchi, Marco Poma, Vincenzo Summa
  • Publication number: 20070167447
    Abstract: The present invention relates to indole and azaindole compounds of formula (I): wherein X1, X2, X3, X4, A1, Ar1, R1, R2 and n are as defined herein, and pharmaceutically acceptable salts thereof, useful in the prevention and treatment of hepatitis C infections.
    Type: Application
    Filed: April 2, 2004
    Publication date: July 19, 2007
    Inventors: Salvatore Avolio, Marcello Di Filippo, Steven Harper, Frank Narjes, Barbara Pacini, Marco Pompei, Michael Rowley, Ian Stansfeld
  • Patent number: 7232819
    Abstract: 4,5-Dihydroxypyrimidine-6-carboxamides of formula (I); are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein R1, R2, R3 and R4 are defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: October 21, 2002
    Date of Patent: June 19, 2007
    Assignee: Istituto Di Ricerche Di Biologia P. Angeletti S.p.A.
    Inventors: Maria E. Di Francesco, Cristina Gardelli, Steven Harper, Victor G. Matassa, Ester Murgalia, Emanuela Nizi, Paola Pace, Barbara Pacini, Alessia Petrocchi, Marco Poma, Vincenzo Summa
  • Publication number: 20070091118
    Abstract: A display system includes a display device and a data processing module. The display device is configured to display an image and has a processing profile associated therewith. The data processing module is remote from and operatively coupled to the display device and is configured to receive input image data for the image to be displayed and generate processed image data from the input image data based on the processing profile of the display device.
    Type: Application
    Filed: October 26, 2005
    Publication date: April 26, 2007
    Inventors: William Allen, James Cole, Steven Harper, Karsten Wilson, Scott Lerner, Anurag Gupta, Jon Brewster
  • Publication number: 20070083045
    Abstract: 4,5-Dihydroxypyrimidine-6-carboxamides of formula: are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein R1, R2, R3 and R4 are defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Application
    Filed: September 7, 2006
    Publication date: April 12, 2007
    Inventors: Maria Di Francesco, Cristina Gardelli, Steven Harper, Victor Matassa, Ester Murgalia, Emanuela Nizi, Paola Pace, Barbara Pacini, Alessia Petrocchi, Marco Poma, Vincenzo Summa
  • Publication number: 20070072911
    Abstract: The present invention relates to indoles and azaindoles of formula (1): wherein X1, X2, X3, X4, A1, Ar1, Ar, n, p and q are as defined herein and pharmaceutically acceptable salts thereof, useful in the prevention and treatment of hepatitis C virus infections.
    Type: Application
    Filed: October 8, 2004
    Publication date: March 29, 2007
    Inventors: Salvatore Avolio, Steven Harper, Frank Narjes, Barbara Pacini, Michael Rowley
  • Patent number: 7119073
    Abstract: Compounds of formula (I), and pharmaceutically acceptable salts and esters thereof: (I); wherein Q, R2, X, Y and Z are as defined herein; are inhibitors of the hepatitis C virus (HCV) NS3 protease
    Type: Grant
    Filed: March 26, 2002
    Date of Patent: October 10, 2006
    Assignee: Istituto Di Ricerche Di Biologia Molecolare P. Angeletti SpA
    Inventors: Stefania Colarusso, Cristina Gardelli, Benjamin Gerlach, Steven Harper, Uwe Koch, Victor Giulio Matassa, Ester Muraglia, Frank Narjes, Jesus Maria Ontoria Ontoria, Alessia Petrocchi, Simona Ponzi, Ian Stansfield, Vicenzo Summa
  • Patent number: 7091209
    Abstract: A class of 2-aryl-4,5-dihydroxy-6-carboxypyrimidines of formula (I): wherein Ar is an optionally substituted aryl or heterocyclicgroup; as well as compounds of formula (I) which are derivatized at one or more of the 4-hydroxy, 5-hydroxy or 6-carboxy groups; and tautomers thereof, and pharmaceutically acceptable salts or esters thereof; and inhibitors of viral polymerases, especially the hepatitis C virus (HCV) polymerase enzyme
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: August 15, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Cristina Gardelli, Claudio Giuliano, Steven Harper, Uwe Koch, Frank Narjes, Jesus Maria Ontoria Ontoria, Marco Poma, Simona Ponzi, Ian Stansfield, Vincenzo Summa